CN111643590B - Collateral activating oil and preparation method thereof - Google Patents

Collateral activating oil and preparation method thereof Download PDF

Info

Publication number
CN111643590B
CN111643590B CN202010385259.8A CN202010385259A CN111643590B CN 111643590 B CN111643590 B CN 111643590B CN 202010385259 A CN202010385259 A CN 202010385259A CN 111643590 B CN111643590 B CN 111643590B
Authority
CN
China
Prior art keywords
oil
weight
parts
test
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010385259.8A
Other languages
Chinese (zh)
Other versions
CN111643590A (en
Inventor
李欢
赵京琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Zhiyu Technology Co ltd
Original Assignee
Tianjin Yunxi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Yunxi Biotechnology Co ltd filed Critical Tianjin Yunxi Biotechnology Co ltd
Priority to CN202010385259.8A priority Critical patent/CN111643590B/en
Publication of CN111643590A publication Critical patent/CN111643590A/en
Application granted granted Critical
Publication of CN111643590B publication Critical patent/CN111643590B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides collateral-activating oil, which comprises 0.1-30 parts by weight of sandalwood seed oil, 0.1-20 parts by weight of angelica oil, 0.1-5 parts by weight of safflower oil, 0.1-5 parts by weight of dragon's blood oil, 0.1-5 parts by weight of ligusticum wallichii oil, 0.1-5 parts by weight of clove oil, 1-50 parts by weight of coconut oil, 1-10 parts by weight of isopropyl palmitate, 1-50 parts by weight of jojoba oil, 0.1-20 parts by weight of peppermint oil, 0.1-20 parts by weight of wintergreen oil, 0.1-20 parts by weight of ginger oil and the balance of olive oil. The invention takes sandalwood seed oil, angelica oil, safflower oil, dragon's blood oil, chuanxiong rhizome oil and clove oil as main components and coconut oil as an auxiliary component, and the lohuo oil of the invention not only has the function of promoting blood circulation by removing blood stasis, but also can improve blood circulation.

Description

Collateral activating oil and preparation method thereof
Technical Field
The invention relates to collateral activating oil and a preparation method thereof, belonging to the technical field of medicinal oil.
Background
In the modern society with increasingly accelerated life pace and doubled working pressure, people do not exercise frequently, and the normal life and work of people are seriously affected by the symptoms of discomfort in shoulders and neck, pain in waist and back and the like caused by long-term bending over of a table. When the symptoms appear, the treatment methods include drug treatment, traction massage physical therapy and operative therapy, wherein the drug treatment has obvious side effects and high price, and has great limitations. The physical treatment effect is unstable and easy to relapse. The operation treatment has great damage to human body, long treatment course and slow recovery.
Traumatic injuries are mainly caused by soft tissue injuries and are accompanied by various swelling pain and distending pain. This is because traumatic injury causes capillary exudation or bleeding, which results in the formation of blood precipitates in the tissue, causing aseptic inflammation, and thus causing pain and swelling of the tissue.
Patent CN20151075850.3 discloses a compound essential oil with functions of eliminating dampness, relieving pain, dredging channels and activating collaterals, which comprises ginger oil, wintergreen oil, rosemary oil, sweet osmanthus flower oil, peppermint oil, grape seed oil and jojoba oil, and mainly has the functions of eliminating dampness and relieving pain.
Patent 201810937548.7 discloses a Chinese herbal medicine preparation for dispelling wind and activating collaterals, eliminating dampness and removing arthralgia, and relieving swelling and pain, which comprises oil of Typhonium giganteum, oleum Cinnamomi, oleum Eucalypti, oleum Caryophylli, safflower oil, Agkistrodon acutus oil, adeps Serpentis, Scolopendra oil, Litsea cubeba oil, radix Angelicae sinensis oil, rhizoma Ligustici Chuanxiong oil, Aloe oil and oleum Menthae Dementholatum, and is mainly a Chinese medicinal preparation for improving blood circulation.
In conclusion, the application of sandalwood seed oil in medicinal oil for relaxing muscles and tendons and promoting blood circulation is not found in the prior art, most of the preparation of the medicinal oil for activating collaterals in the prior art are traditional Chinese medicine components, and the medicinal oil has certain effects of promoting blood circulation and removing blood stasis, but rarely has an anti-inflammatory repair effect, and has certain defects in relieving chronic pain.
Disclosure of Invention
Aiming at the defects in the prior art, the first purpose of the invention is to provide the collateral-activating oil with anti-inflammatory and antioxidant repair functions.
The second purpose of the invention is to provide a preparation method of the collateral activating oil.
In order to achieve the first object, the invention is realized by the following technical scheme: the collateral activating oil comprises the following components:
Figure BDA0002483574700000021
preferably, the composition comprises the following components:
Figure BDA0002483574700000022
further, the auxiliary material for the collateral activating oil also comprises 1-50 parts by weight of coconut oil.
Preferably, the coconut oil accounts for 10-40 parts by weight.
Further, the oil-water retention agent also comprises 1-10 parts by weight of isopropyl palmitate.
Preferably, the isopropyl palmitate is 5-8 parts by weight.
Further, the composition also comprises an auxiliary material for the collateral activating oil, wherein the auxiliary material for the collateral activating oil comprises the following components:
Figure BDA0002483574700000023
Figure BDA0002483574700000031
preferably, the auxiliary materials for the collateral activating oil comprise the following components:
Figure BDA0002483574700000032
further, the collateral activating oil comprises the following components:
Figure BDA0002483574700000033
the technical scheme has the following main components in effect and characteristics:
(1) sandalwood seed oil
The sandalwood seed oil adopted by the technical scheme is natural grease extracted from sandalwood (SANTALUM SPICATUM) fruits, and 30-35% of the sandalwood seed oil can be extracted from the sandalwood fruits by a carbon dioxide supercritical extraction method. The sandalwood seed oil is a natural mixture of ximenynic acid, oleic acid and a small amount of other common fatty acids, and is a natural vegetable oil containing unsaturated fatty acids with triple bond structures. It contains 30-35% ximenynic acid, which is a natural C18 fatty acid with triple bond at position 9. Ximenynic acid has antiinflammatory, anticancer, and antiaging effects. The sandalwood seed oil can sterilize and diminish inflammation, and prevent and treat carbuncle swelling.
200 kg of essential oil can be produced by the mature sandalwood, the essential oil produced at the root is 6-7%, and the core material is 2-5%. The sandalwood essential oil can reach proper maturity and fragrance after being distilled out and stored for 6 months, the color is changed from light yellow to yellow brown, and the sandalwood essential oil is thick, sweet and fragrant and has natural fruit flavor. The sandalwood essential oil has antibacterial effect, and can improve skin itching, inflammation and other symptoms.
(2) Angelica sinensis oil
The angelica oil has the effects of enriching and activating blood, promoting blood circulation, relieving vascular smooth muscle spasm, resisting inflammation and easing pain, relieving asthma, protecting liver and benefiting gallbladder, and the like, and through detection and analysis, 52 components are identified in the angelica oil, wherein the most main component is ligustilide with the content of 45-65%, the angelica oil has good analgesic and anti-inflammatory effects, and the ligustilide is a main drug effect substance.
(3) Dragon's blood oil
Sanguis Draxonis is prepared from resin exuded from fruit of daemonorops draco of Palmaceae. Distributed in java, sumatra, borneo, etc. in indonesia. Has effects of promoting blood circulation, relieving pain, removing blood stasis, stopping bleeding, promoting granulation, and healing sore. Can be used for treating traumatic injury, heart and abdomen blood stasis and pain, traumatic hemorrhage, and unhealed skin and external diseases.
(5) Ligusticum wallichii oil
The ligusticum wallichii is a traditional Chinese medicine material capable of dispelling wind, relieving pain and dredging channels and collaterals, and when rheumatic bone pain or rheumatic arthritis occurs, a proper amount of ligusticum wallichii oil can be directly taken, or the ligusticum wallichii oil can be smeared on the painful joints and is massaged moderately, so that swelling and pain can be relieved after the ligusticum wallichii oil is used, and symptoms such as limb numbness and the like caused by the blockage of channels and collaterals can also be relieved.
(6) Palmitic acid isopropyl ester
Used as additive and solubilizer. Isopropyl palmitate has stable performance and is not easy to oxidize to generate peculiar smell. Has good permeability to skin.
(7) Coconut oil
Oil from coconut palm the endosperm of the coconut, a palm plant, is crushed and steamed to extract oil. Is easily absorbed by skin, and has skin and hair caring effects.
The sandalwood seed oil, the angelica oil, the safflower oil, the dragon's blood oil, the ligusticum wallichii oil and the clove oil are used as main components, the coconut oil is used as an auxiliary component, the solubilizer isopropyl palmitate is added, other auxiliary materials for activating collaterals oil commonly used in the field are used as auxiliary materials, the added isopropyl palmitate can uniformly disperse the oily substances to form a stable solution, and tests show that the lolo huo oil not only has the functions of activating blood and dissolving stasis, but also has the functions of resisting inflammation and oxidation and repairing, and can continuously relieve chronic pain.
In order to achieve the second object, the invention is realized by the following technical scheme: a preparation method of collateral activating oil comprises the following steps:
the method comprises the following steps: mixing the sandalwood seed oil, the angelica oil, the safflower oil, the dragon's blood oil, the ligusticum wallichii oil and the clove oil according to a proportion, and stirring until the mixture is uniformly mixed to obtain a mixture A;
step two: and (3) sequentially adding jojoba oil, coconut oil, peppermint oil, wintergreen oil, ginger oil and isopropyl palmitate into the mixture A prepared in the step one, and stirring to obtain the collateral-activating oil product.
The invention has the beneficial effects that:
(1) the invention takes sandalwood seed oil, angelica oil, safflower oil, dragon's blood oil, chuanxiong rhizome oil and clove oil as main components and coconut oil as an auxiliary component, and the lohuo oil of the invention not only has the function of promoting blood circulation by removing blood stasis, but also can improve blood circulation.
(2) According to the invention, the sandalwood seed oil is matched, so that the finished product collateral activating oil has anti-inflammatory and antioxidant effects, and can realize the effect of continuously relieving pain.
Drawings
FIG. 1 is a graph showing the results of the mouse auricle swelling test in test example 1 of the present invention.
FIG. 2 is a graph showing the results of the analgesic test of mouse in test example 1 of the present invention.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments.
Examples 1-8, the Huoluo oil components are detailed in Table 1.
TABLE 1 EXAMPLE 8 component contents
Figure BDA0002483574700000061
The preparation method comprises the following steps:
the method comprises the following steps: mixing the sandalwood seed oil, the angelica oil, the safflower oil, the dragon's blood oil, the ligusticum wallichii oil and the clove oil according to a proportion, and stirring until the mixture is uniformly mixed to obtain a mixture A;
step two: and (3) sequentially adding jojoba oil, coconut oil, peppermint oil, wintergreen oil, ginger oil and isopropyl palmitate into the mixture A prepared in the step one, and stirring to obtain the collateral-activating oil product.
Test example 1 mouse auricular swelling test
The test animals were: 80 mice 18-20g, SPF grade, female halves.
The experimental method comprises the following steps: the mice are randomly divided into 8 groups of 10 mice, the groups are marked as a blank control group, a positive control group and a test group 5-a test group 10, and the components of the collateral activating oil of the test examples 5-10 are detailed in a table 2. Wherein: the left ear of the blank control group mouse is evenly coated with 10 mu g of soybean oil on both sides, the left ear of the positive control group mouse is evenly coated with 10 mu g of safflower oil on both sides, and the left ear of the test group 5-test group 10 mouse is evenly coated with 10 mu g of the collateral activating oil prepared in the test example 5-test example 10 on both sides. Smearing 1 time/day, continuously administering for 5 days, after administering for 1h, smearing 50 μ g/mouse of diphenyl oxide on left ear, killing mouse after 2h, punching round ear piece with 8mm diameter punch on the same part of left and right ears of mouse, and weighing, the result is shown in figure 1.
TABLE 2 test example 5 to test example 10 contents of each component
Figure BDA0002483574700000071
Swelling rate ═ weight of left ear-weight of right ear)/weight of right ear.
The swelling rate of the blank control group is 50.33%, the swelling rate of the positive control group is 26.12%, as shown in fig. 1, the swelling rate of the mice gradually decreases with the increase of the sandalwood seed oil content, the sandalwood seed oil content is within 0-30g, the swelling rate obviously decreases with the increase of the sandalwood seed oil content, and when the sandalwood seed oil content is more than 30g, the swelling rate slowly decreases with the increase of the sandalwood seed oil content.
Test example 2 analgesic test in mice
The test animals were: 80 mice 18-20g, SPF grade, male and female halves.
The experimental method comprises the following steps: the temperature of the hotplate instrument was adjusted to 55 + -5 deg.C as a thermal stimulus. Screening qualified mice: each time, 1 mouse was placed on the hot plate and the time(s) required for the mouse to reach the paw after licking was taken as the pain threshold for that mouse. The average value was taken as the pain threshold before administration to the mice. Dividing qualified mice into 8 groups, wherein each group comprises 10 mice, and marking the mice as a blank control group, a positive control group, a test group 11-a test group 16, wherein: the positive control group is coated with safflower oil, the test groups 11 to 16 are respectively coated with the collateral activating oil prepared in the test examples 11 to 16, and the contents of the components in the test examples 11 to 16 are shown in Table 3. The pain threshold of each group of mice was measured at 30min, 60min, 120min of administration, respectively, and the pain threshold time was recorded as 60s when it exceeded 60 s. The test results are shown in FIG. 2.
Inhibition rate ═ pain threshold in test group-pain threshold in blank control group)/pain threshold in blank control group.
TABLE 3 TEST EXAMPLE 11-TEST EXAMPLE 16 contents of respective components
Figure BDA0002483574700000081
The inhibition rate of the positive control group is 22.73%, as can be seen from fig. 2, the collateral-activating oil prepared by the invention has good analgesic effect, the inhibition rate gradually increases with the increase of the addition amount of the dragon's blood oil, and when the addition amount of the dragon's blood oil is more than 5g, the increase of the inhibition rate is slowed down.
Test example 3 skin irritation test
(1) One time skin irritation test
The test animals were: 10 rats, half male and female, weighing 180-.
The experimental method comprises the following steps: the hair on both sides of the spine of the rat is removed by depilatory without damaging the skin, and the hair removal range is about 3cm multiplied by 3cm respectively. The collaterals-activating oil drops prepared in example 3 were directly applied to gauze with an area of 2.5cm × 2.5cm, and then applied to the surface of the skin with hair removed on the right side, and then fixed with a non-irritating adhesive tape for 24h, with the hair-removed area on the left side as a control, and the animals were observed for signs of poisoning for 7 days.
The results show that the rats are not dead and LD is not existed after the application of the collateral activating oil prepared in the example 3 of the invention50> 5000mg/kg body weight.
(2) Multiple skin irritation test
The test animals were: 10 rats, half male and female, weighing 180-.
The experimental method comprises the following steps: the hair on both sides of the spine of the rat is removed by depilatory without damaging the skin, and the hair removal range is about 3cm multiplied by 3cm respectively. The collaterals-activating oil prepared in example 3 was directly dropped on gauze having an area of 2.5cm × 2.5cm, and applied to the surface of the depilated skin on the right side, and then fixed with a non-irritating adhesive tape for 1 hour, while the depilated area on the left side was used as a control, once a day for 14 days, and the skin irritation reaction results were observed.
The results show that the skin is not abnormal and does not become red after the application of the collateral activating oil prepared in the embodiment 3 of the invention, which indicates that the collateral activating oil prepared in the invention has no irritation.
And after applying commercially available safflower oil 10 times, the skin reddened.
(3) Primary damaged skin irritation test
The test animals were: 10 rats, half male and female, weighing 180-.
The test substance: the collateral activating oil prepared in example 3.
The experimental method comprises the following steps: before applying the test substance, cleaning and sterilizing the exposed skin with 75% on the depilated skin of 3cm × 3cm, scratching a 'well' -shaped damaged wound in the skin area with a sterilizing blade or an injection needle after the alcohol is volatilized, and infecting the damaged skin area with the drug. Note that the skin is damaged only to the epidermis, and the dermis is not damaged. The following day the test article was smeared on the right skin, the left was used as a control, and the skin condition was observed after 24 hours.
The result shows that the skin does not have obvious redness after the collateral activating oil prepared in the embodiment 3 of the invention is applied, and the collateral activating oil prepared in the invention has no irritation.
Test example 4 mouse writhing response
The tested animals comprise 60 mice of 18-20g, SPF grade, and male and female halves.
The experimental method comprises the following steps: the mice were randomly divided into 6 groups, designated as blank control group, positive control group, test group 1, test group 2, test group 3 and test group 4, the content of the components of test example 1-test example 4 is detailed in table 4, and a 2cm x 2cm skin bare area was shaved on the abdomen of the mice with a razor, wherein: the blank group was given purified water of the same volume, the positive group was given safflower oil, test group 1 to test group 4 were applied with the collateral-activating oil prepared in test example 1 to test example 4, 1 time/day, and 5 days were continuously administered, 0.2mL of 0.6% glacial acetic acid solution was injected into each abdominal cavity, and the number of writhing of each group of mice within 20min after injection of the analgesic agent was recorded, and the results are shown in table 5.
Table 4 test example 1 to test example 4 contents of each component
Addition amount/g Test example 1 Test example 2 Test example 3 Test example 4
Sandalwood seed oil — 5 5 —
Angelica sinensis oil 5 5 5 5
Safflower oil 5 5 5 5
Dragon's blood oil 3 — 3 —
Ligusticum wallichii oil 2 2 2 2
Clove oil 3 3 3 3
Coconut oil 10 10 10 10
Palmitic acid isopropyl ester 5 5 5 5
Jojoba oil 30 30 30 30
Mint oil 10 10 10 10
Wintergreen oil 10 10 10 10
Ginger oil 5 5 5 5
Olive oil Make up to 100g Make up to 100g Make up to 100g Make up to 100g
TABLE 5 Effect of activating oil on mouse writhing frequency (mean. + -. s)
Group of Dosage (mg/cm)2) Number of times of body twisting
Blank control group — 22.9±3.1
Positive control 1 11.5±2.1
Test group 1 1 16.38±2.2
Test group 2 1 14.11±3.1
Test group 3 1 10.66±2.0
Test group 4 1 17.33±1.9
As can be seen from table 5, the number of writhing of mice in test group 1 without sandalwood seed oil and test group 4 without sandalwood seed oil and dragon's blood oil is the largest, the number of writhing of mice in test group 2 without dragon's blood oil is the smallest, and the number of writhing of mice in test group 3 with sandalwood seed oil and dragon's blood oil is the smallest, which indicates that the pain-relieving and anti-inflammatory effects of test group 1 and test group 4 are the worst, and the pain-relieving and anti-inflammatory effects of test group 3 are the best, and experiments show that sandalwood seed oil and dragon's blood oil have good anti-inflammatory effects and pain-relieving effects.
While there have been shown and described what are at present considered the fundamental principles and essential features of the invention and its advantages, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing exemplary embodiments, but is capable of other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.

Claims (2)

1. The collateral activating oil is characterized by comprising the following components:
Figure FDA0003364202320000011
2. a method for preparing the collateral activating oil of claim 1, comprising the steps of:
the method comprises the following steps: mixing the sandalwood seed oil, the angelica oil, the safflower oil, the dragon's blood oil, the ligusticum wallichii oil and the clove oil according to a proportion, and stirring until the mixture is uniformly mixed to obtain a mixture A;
step two: and (3) sequentially adding jojoba oil, coconut oil, peppermint oil, wintergreen oil, ginger oil and isopropyl palmitate into the mixture A prepared in the step one, and stirring to obtain the collateral-activating oil product.
CN202010385259.8A 2020-05-09 2020-05-09 Collateral activating oil and preparation method thereof Active CN111643590B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010385259.8A CN111643590B (en) 2020-05-09 2020-05-09 Collateral activating oil and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010385259.8A CN111643590B (en) 2020-05-09 2020-05-09 Collateral activating oil and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111643590A CN111643590A (en) 2020-09-11
CN111643590B true CN111643590B (en) 2022-02-25

Family

ID=72340740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010385259.8A Active CN111643590B (en) 2020-05-09 2020-05-09 Collateral activating oil and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111643590B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1451421A (en) * 2002-04-12 2003-10-29 解其珍 Chinese medicine plaster for treating ostealgia
CN102205021A (en) * 2011-05-20 2011-10-05 王德斌 Collateral-moistering bone-penetrating oil
CN103479775A (en) * 2013-09-26 2014-01-01 山东三星玉米产业科技有限公司 Scraping liniment and preparation method thereof
CN106668818A (en) * 2017-01-25 2017-05-17 王亮 Herbal curing cream
CN107951963A (en) * 2017-12-08 2018-04-24 广州圣芳医药科技有限公司 A kind of health oil
CN110327438A (en) * 2019-07-19 2019-10-15 广州艾蓓生物科技有限公司 One kind is releived massage cream
CN110787202A (en) * 2019-12-02 2020-02-14 湖北艾仙乐生物科技有限责任公司 Wind-dispelling and collateral-activating oil
CN111073754A (en) * 2019-09-12 2020-04-28 天津芸熙生物技术有限公司 Method for extracting sandalwood seed oil from macadamia ternifolia fruits

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105999013B (en) * 2016-07-28 2020-02-07 海南娜古芳沉香科技有限公司 Agilawood collateral-activating oil and preparation method thereof
CN111073941B (en) * 2019-09-12 2022-10-14 天津芸熙生物技术有限公司 Preparation process of sandalwood polypeptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1451421A (en) * 2002-04-12 2003-10-29 解其珍 Chinese medicine plaster for treating ostealgia
CN102205021A (en) * 2011-05-20 2011-10-05 王德斌 Collateral-moistering bone-penetrating oil
CN103479775A (en) * 2013-09-26 2014-01-01 山东三星玉米产业科技有限公司 Scraping liniment and preparation method thereof
CN106668818A (en) * 2017-01-25 2017-05-17 王亮 Herbal curing cream
CN107951963A (en) * 2017-12-08 2018-04-24 广州圣芳医药科技有限公司 A kind of health oil
CN110327438A (en) * 2019-07-19 2019-10-15 广州艾蓓生物科技有限公司 One kind is releived massage cream
CN111073754A (en) * 2019-09-12 2020-04-28 天津芸熙生物技术有限公司 Method for extracting sandalwood seed oil from macadamia ternifolia fruits
CN110787202A (en) * 2019-12-02 2020-02-14 湖北艾仙乐生物科技有限责任公司 Wind-dispelling and collateral-activating oil

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
西木门炔酸的分离、提纯与鉴定;蔡芳;《博士学位论文全文库——工程科技Ⅰ辑》;20170215(第02期);第9页倒数第3-4段 *
西红花活络油的制备与质量控制初步研究;袁松涛;《中成药》;19970220;第19卷(第02期);第14-15页 *

Also Published As

Publication number Publication date
CN111643590A (en) 2020-09-11

Similar Documents

Publication Publication Date Title
US6027728A (en) Herbal skin regeneration composition and method
WO1993011780A1 (en) Skin therapeutic mixture containing cold-processed aloe vera extract, with yellow sap and aloin removed
CN104434740B (en) A kind of Chinese medicine blemish clearing gel agent and preparation method thereof
KR100990195B1 (en) Allergic or atopic dermatitis-alleviating natural cosmetic composition
Solanki Treatment of skin diseases through medicinal plants in different regions of the world
CN112773820A (en) Emu medicine essential oil for diminishing inflammation and easing pain and preparation method thereof
CN114146014B (en) Compound menthyl nicotinate plant polysaccharide emulsifiable paste and preparation method thereof
CN100534511C (en) Combined Chinese-Western medicine mixture for treating mycotic skin disease, and its use method
KR20150060487A (en) Oriental plant extracts for attenuating pain
CN111643590B (en) Collateral activating oil and preparation method thereof
CN108938511B (en) Composition of natural plant extracts and application of composition in skin moisturizing and acne removing products
CN110974861A (en) Blumea balsamifera oil liposome
US9421235B2 (en) Medicine containing extracts of Ficus microcarpa for healing wounds of a diabetic patient
CN110013459A (en) A kind of skin care compositions containing Turmeric and have effects that subtract the skin care item of wrinkle
US11154583B2 (en) Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies
US20160106798A1 (en) Topical treatment for use in conjunction with acupuncture or acupressure therapy
CN113599498A (en) Composite antibacterial peptide and preparation method thereof, and bee venom conditioning cream capable of rapidly relieving pain and preparation method thereof
CN114129649A (en) Cold compress gel capable of promoting skin barrier repair and nursing
CN110624031A (en) Essential oil for lowering essence, nourishing meridian and health care
CN111700972A (en) Acne-removing traditional Chinese medicine composition and preparation method thereof
Srivastav et al. Prevention and cure of dermatology disorders using herbal medications: summary
CN110478434A (en) A kind of Chinese medicine composition, pharmaceutical preparation and its application
RU2128990C1 (en) Anti-inflammatory and wound-healing ointment "vundehil"
CN108853293B (en) Compound essential oil for treating hemorrhoids and preparation method and use method thereof
CN118267322B (en) Traditional Chinese medicine composition with striae gravidarum repairing effect and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240531

Address after: 300000 Tianjin Binhai New Area Zhongxin Ecological City Anming Road and Anye West Road Intersection Binhai Life Valley East Area No. 4 Factory Building 1-2 Floors

Patentee after: Tianjin Zhiyu Technology Co.,Ltd.

Country or region after: China

Address before: Room 203, block C6, Tianda science and Technology Park, 80 Fourth Street, Binhai New Area Economic and Technological Development Zone, Tianjin 300450

Patentee before: TIANJIN YUNXI BIOTECHNOLOGY CO.,LTD.

Country or region before: China